A Phase 1 Dose Escalation Study of the Oral Selective Inhibitor of Nuclear Export (SINE) KPT-330 (selinexor) in Patients with Heavily Pretreated Non-Hodgkin’s Lymphoma (NHL)
A Phase 1 Dose Escalation Study of the Oral Selective Inhibitor of Nuclear Export (SINE) KPT-330 (selinexor) in Patients with Heavily Pretreated Non-Hodgkin’s Lymphoma (NHL)